Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care

References

• Davidson JA. The increasing role of primary care physicians in caring for patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010;85(12 Suppl):S3–S4.
   PubMedGoogle Scholar
• Holman RR, Turner RC. Diabetes: the quest for basal normoglycaemia. Lancet. 1977;1(8009):469–474.
   PubMed Web of Science ®Google Scholar
• Cheng AYY, Patel DK, Reid TS, et al. Differentiating basal insulin preparations: understanding how they work explains why they are different. Adv Ther. 2019;36(5):1018–1030.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes – 2021. Diabetes Care. 2021;44(Suppl. 1):S111–S124.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529.
   PubMed Web of Science ®Google Scholar
• Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411–3417.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543–2545.
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673–2679.
   PubMed Web of Science ®Google Scholar
• Ratanawongsa N, Crosson JC, Schillinger D, et al. Getting under the skin of clinical inertia in insulin initiation: the Translating Research Into Action for Diabetes (TRIAD) Insulin Starts Project. Diabetes Educ. 2012;38(1):94–100.
   PubMed Web of Science ®Google Scholar
• Sorli C, Heile MK. Identifying and meeting the challenges of insulin therapy in type 2 diabetes. J Multidiscip Health. 2014;7:267–282.
   PubMedGoogle Scholar
• Zafar A, Stone MA, Davies MJ, et al. Acknowledging and allocating responsibility for clinical inertia in the management of type 2 diabetes in primary care: a qualitative study. Diabet Med. 2015;32(3):407–413.
   PubMed Web of Science ®Google Scholar
• Seidu S, Than T, Kar D, et al. Therapeutic inertia amongst general practitioners with interest in diabetes. Prim Care Diabetes. 2018;12(1):87–91.
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29(6):1269–1274.
   PubMed Web of Science ®Google Scholar
• Owens DR, Traylor L, Mullins P, et al. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100 U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Res Clin Pract. 2017;124(Supplement C):57–65.
   PubMed Web of Science ®Google Scholar
• Ritzel R, Roussel R, Giaccari A, et al. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab. 2018;20(3):541–548.
   PubMed Web of Science ®Google Scholar
• Wysham C, Bhargava A, Chaykin L, et al. Effect of insulin degludec vs. insulin glargine u100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318(1):45–56.
   PubMed Web of Science ®Google Scholar
• Berard L, Antonishyn N, Acurdi K, et al. Insulin matters: a practical approach to basal insulin management in type 2 diabetes. Diabetes Ther. 2018;9(2):501–519.
   PubMed Web of Science ®Google Scholar
• Kuritzky L, Reid TS, Wysham CH. Practical guidance on effective basal insulin titration for primary care providers. Clin Diabetes. 2019;37(4):368–376.
   PubMedGoogle Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701.
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Parker MM, Moffet HH, et al. Association of initiation of basal insulin analogs vs. neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes. JAMA. 2018;320(1):53–62.
   PubMed Web of Science ®Google Scholar
• LaSalle JR. Empowering patients during insulin initiation: a real-world approach. J Am Osteopath Assoc. 2010;110(2):69–78.
   PubMedGoogle Scholar
• Food and Drug Administration. Basaglar® prescribing information. [cited 2020 Sep 15]. Available from: https://uspl.lilly.com/basaglar/basaglar.html#pi
   Google Scholar
• Food and Drug Administration. Lantus® prescribing information. [cited 2020 Sep 15]. Available from: http://products.sanofi.us/Lantus/Lantus.html
   Google Scholar
• Food and Drug Administration. Tresiba® prescribing information. [cited 2020 Sep 15]. Available from: https://www.novo-pi.com/tresiba.pdf
   Google Scholar
• Food and Drug Administration. Toujeo® prescribing information. [cited 2020 Sep 15]. Available from: http://products.sanofi.us/Toujeo/Toujeo.pdf
   Google Scholar
• Food and Drug Administration. Levemir® prescribing information. [cited 2020 Sep 15]. Available from: https://www.novo-pi.com/levemir.pdf
   Google Scholar
• Meneghini L, Atkin SL, Gough SCL, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36(4):858–864.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Bolli GB, Home PD, et al. Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetes. Diabetes Technol Ther. 2016;18(4):252–257.
   PubMed Web of Science ®Google Scholar
• Diabetes Canada. Building competency in diabetes education: the essentials. 2016. Chapter 8, Saskatchewan advanced insulin dose adjustment module: p. 17–18. [cited 2020 Aug 18]. Available from: https://www.ehealthsask.ca/services/resources/Resources/advanced-insulin-dose-adjustment-module.pdf
   Google Scholar
• Philis-Tsimikas A. Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control. Am J Med. 2013;126(0 ):S21–S27.
   PubMed Web of Science ®Google Scholar
• Beato-Víbora PI, Arroyo-Díez FJ. New uses and formulations of glucagon for hypoglycaemia. Drugs Context. 2019;8:212599.
   PubMedGoogle Scholar
• Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. Mayo Clin Proc. 2016;91(9):1231–1255.
   PubMed Web of Science ®Google Scholar
• Trief PM, Cibula D, Rodriguez E, et al. Incorrect insulin administration: a problem that warrants attention. Clin Diabetes. 2016;34(1):25–33.
   PubMedGoogle Scholar
• Castellana M, Procino F, Sardone R, et al. Efficacy and safety of patient-led versus physician-led titration of basal insulin in patients with uncontrolled type 2 diabetes: a meta-analysis of randomized controlled trials. BMJ Open Diabetes Res Care. 2020;8(1):e001477.
   PubMed Web of Science ®Google Scholar
• Patel D, Triplitt C, Trujillo J. Appropriate titration of basal insulin in type 2 diabetes and the potential role of the pharmacist. Adv Ther. 2019;36(5):1031–1051.
   PubMed Web of Science ®Google Scholar
• Yale JF, Berard L, Groleau M, et al. TITRATION: a randomized study to assess 2 treatment algorithms with new insulin glargine 300 units/ml. Can J Diabetes. 2017;41(5):478–484.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas: the Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med. 2006;23(7):736–742.
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhao Y, Du T, et al. Lack of coordination between partners: investigation of Physician-Preferred and Patient-Preferred (4P) basal insulin titration algorithms in the real world. Patient Prefer Adherence. 2018;12:1253–1259.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl. 1):S66–S76.
   PubMed Web of Science ®Google Scholar
• Bajaj S, Das AK, Kalra S, et al. BE-SMART (Basal Early Strategies to Maximize HbA1c Reduction with Oral Therapy). Diabetes Ther. 2019;10(4):1189–1204.
   PubMed Web of Science ®Google Scholar
• Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384(9961):2228–2234.
   PubMed Web of Science ®Google Scholar
• Maiorino MI, Chiodini P, Bellastella G, et al. Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2017;40(4):614–624.
   PubMed Web of Science ®Google Scholar
• Royal Cornwall Hospitals NHS Trust. Care of adults with diabetes who require bowel preparation clinical guideline. V4.0. 2019. [cited 2021 Jun 15]. Available from: https://doclibrary-rcht.cornwall.nhs.uk/DocumentsLibrary/RoyalCornwallHospitalsTrust/Clinical/EndocrineAndDiabetes/CareOfAdultsWithDiabetesWhoRequireBowelPreparationClinicalGuideline.pdf
   Google Scholar
• Goldenberg R, Aroda VR, Billings LK. Effect of insulin degludec U100 vs. insulin glargine U100 on time in range in patients with type 2 diabetes at risk of hypoglycaemia. Diabetologia. 2020;63(Suppl):S318–S319.
   Web of Science ®Google Scholar
• Umpierrez GE, Holt EH, Einhorn D, et al. Concentrated insulins: clinical update of therapeutic options. Endocrine Pract. 2020;26(Suppl. 3):1–12.
   PubMed Web of Science ®Google Scholar
• Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723–732.
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487–493.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Soliqua® prescribing information. [cited 2020 Sep 15]. Available from: http://products.sanofi.us/soliqua100-33/Soliqua100-33.pdf
   Google Scholar
• Food and Drug Administration. Xultophy® 100/3.6 prescribing information. [cited 2020 Sep 15]. Available from: https://www.novo-pi.com/xultophy10036.pdf
   Google Scholar
• Lingvay I, Pérez Manghi F, García-Hernández P, et al. Effect of insulin glargine up-titration vs. insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes the DUAL V randomized clinical trial. JAMA. 2016;315(9):898–907.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Russell-Jones D, Barber TM, et al. Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial. Diabetes Obes Metab. 2019;21(8):1967–1972.
   PubMed Web of Science ®Google Scholar
• Kalra S. Insulin degludec aspart: the first co-formulation of insulin analogues. Diabetes Ther. 2014;5(1):65–72.
   PubMed Web of Science ®Google Scholar